Our helpline: 01924 200799 Mon-Fri, 9am-4pm


Photo: Jan Chlebik for the ICR


The Alife2 study is investigating whether anti-coagulant (blood–thinning) treatment reduces the risk of miscarriage in women with two or more (unexplained) miscarriages and inherited thrombophilia – a blood-clotting problem.

The MifeMiso trial

The MifeMiso trial is an important research study which is looking at whether a single drug treatment (misoprostol) or a combination of drug treatments (mifepristone plus misoprostol two days later) is best for the medical management of missed miscarriage. We provide information about it below, and you can read more about medical management of miscarriage […]

The PRISM trial

The PRISM trial is an important research study which is looking at whether progesterone can prevent miscarriage in women with early pregnancy bleeding.

The RESPONSE trial

The RESPONSE trial is testing a new medication, called NT100, in women with unexplained repeated miscarriages.

The TABLET trial

The TABLET trial is an important research study which is looking at the role of thyroid antibodies in women with unexplained miscarriage.

The PROMISE trial

A clear result – Progesterone supplements in the first trimester of pregnancy do NOT improve outcomes in women with a history of unexplained recurrent miscarriages.

Improving psychological wellbeing

Sarah Bailey describes a different type of research study which is looking at trying to improve the psychological wellbeing of women who have suffered recurrent miscarriage.

Talking about research

Ruth interviews Professor Arri Coomarasamy, Consultant Gynaecologist and Sub-specialist in Reproductive Medicine and Surgery at Birmingham Women’s Hospital.

Priorities for miscarriage research

In recent years, there has been more research done into causes of and potential treatments for miscarriage, but there remain many unanswered questions. Just what should researchers be looking at in the area of miscarriage? What should the research priorities be? Miscarriage Association Trustee Barbara Hepworth-Jones writes: The Miscarriage Association (M.A.) has been involved in […]